Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if giving an experimental drug called venetoclax in
combination with lenalidomide and rituximab is safe and effective for treating people with
Mantle Cell Lymphoma (MCL).
Phase:
Phase 1
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center